
What smart money is saying about Ossdsign
1 fund in our archive has pitched Ossdsign — most recently Protean Funds in June 2025.
OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. The company's products include OSSDSIGN cranial, an implant solution and related accessories for skull defect reconstruction in cranioplasty patients; and OSSDSIGN facial to treat post-traumatic skeletal deformities and congenital skeletal defects. It also offers OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage; and OssDsign Catalyst, a nanosynthetic bone graft substitute that stimulates the formation of healthy bone tissue. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.
Get an email when a fund writes about it
Position history
Between Q2 2025 and Q2 2026, 1 fund letter reported a position in Ossdsign, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q2 2025 | 0 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsProtean Funds Partner LetterApril 2026
“and a position in OssDsign which reported so-so figures during what hopefully is a transition phase.”
Read the letterOssdsign
Fund coverage · 1 thesis
- Protean FundsJune 2025
Ossdsign is a promising Swedish medtech company with strong growth potential, evidenced by encouraging one-year fusion rates of 88% for its nanosynthetic bone graft used in spinal fusion surgeries.
Read the full thesis
Read every full thesis on Ossdsign
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→